AMGN — Amgen Inc.

The market is bullish following the August 4 Q2 2026 beat: total revenue rose 10% y/y to $10.05B, non-GAAP EPS of $6.29 beat the $5.62 consensus, and management raised FY26 non-GAAP EPS guidance to $22.30-$23.50. Wall Street has responded with price-target hikes, including Argus at $460 and Piper Sandler at $457, even though the broader consensus target of roughly $386-387 is still below spot.

Revenue is accelerating, not just stable. Quarterly revenue has grown from $6.90B in Sep-2023 to $10.05B in Jun-2026, with TTM revenue around $38.1B. Q2 2026 grew roughly 10% y/y after Q1 2026 grew only ~5.8%, so the pace reaccelerated. Operating margin has expanded to 33.2% TTM, and Q2 2026 operating margin was about 35%. GAAP EPS is noisy due to one-off items—Q1 2024 was -$0.21, Q4 2025 was $2.45, Q2 2026 was $4.37—but non-GAAP EPS is climbing and guidance was raised. The mix is also shifting structurally: six growth drivers grew 26% y/y and now make up ~70% of product sales, while Prolia/Xgeva fell 33% on biosimilar competition.

As of 2026-08-27, the stock is rich on trailing metrics: P/E is 26.9x vs. its 5-year average of 24.7x, and P/S is 6.2x vs. a 5-year average of 5.0x. But trailing GAAP earnings are depressed by charges. On the raised FY26 EPS guidance midpoint of $22.90, forward P/E is ~19.1x, and on the next-fiscal-year consensus of $23.08 it is ~18.9x. That is reasonable for the growth rate, but not cheap; the historical comparisons say expensive.

The stock has run from $269.77 to nearly $447 and, as of 2026-08-27, trades about 13% above the consensus analyst target near $387. The market is paying in advance for the raised guidance and, more importantly, for MariTide obesity optionality. If the growth story continues but MariTide disappoints, the air pocket is roughly 17x forward EPS, or about $390. If MariTide Phase 3 data are positive, the multiple can stay above 20x and the stock can push to $460+. Right now, the price is already embedding a fairly high probability of pipeline success.

As of 2026-08-27, RSI was 68.12, price was 4.27% above the 20-day SMA, 13.19% above the 50-day SMA, and 22.96% above the 200-day SMA. That is a strong uptrend that has become extended in the short term. RSI is close to overbought but not yet above 70. Chasing right here is poor timing risk; a pullback toward the 20-day or 50-day would offer a better entry.

• Interest-rate sensitivity: Amgen carries $51.9B in long-term debt and a 4.9 debt-to-equity ratio, so high-for-longer rates keep leverage and interest costs a live concern.
• Defensive rotation: With a 0.41 beta, a 2.3% dividend yield, and $3.5B of FCF in Q2 alone, Amgen is a safe-haven large-cap pharma in volatile markets.
• GLP-1/obesity sentiment: MariTide is a major valuation swing factor, while Eli Lilly and Novo Nordisk still have far more commercial manufacturing scale.
• US drug pricing and IRA negotiation risk: structural pressure on realized prices remains a recurring overhang.
• Biosimilar erosion: Prolia/Xgeva already fell 33% y/y, and further erosion in mature brands is a steady drag on the base business.

• MariTide Phase 3 weight-loss and Type 2 diabetes data/updates expected later in 2026 - the primary binary catalyst.
• Q3 2026 earnings around November 3, 2026, with consensus EPS near $5.76.
• Continued 20%+ growth from Repatha, Evenity, Tezspire, Uplizna, Imdelltra, and biosimilars.
• CFO transition to Thomas Dittrich in Q3 2026 - could create minor execution noise or pass smoothly.

• MariTide Phase 3 failure or a weaker-than-expected efficacy/safety profile would deflate the obesity premium in the stock.
• Biosimilar competition accelerating across Amgen's mature bone franchise and other legacy products.
• High leverage limits financial flexibility and makes earnings more sensitive to rising rates or a debt downgrade.
• IRA drug price negotiation and broader US pricing pressure could compress margins despite volume growth.

Amgen is a good business that has recently become a less obvious buy. The operating fundamentals are strong - accelerating revenue, expanding margins, robust free cash flow, and raised guidance - but as of 2026-08-27 the stock is near its 52-week high and priced for both execution and MariTide success. I lean cautiously bullish: own it for the quality and cash flow, but add on weakness rather than chase the strength ahead of the binary pipeline readout.

I used a two-stage FCF model: TTM FCF of $10.18B, 6% FCF growth for five years, 3% terminal growth, and a 7.5% discount rate, producing an enterprise value around $266B. Subtracting net debt of $37.87B and dividing by ~539.7M shares gives roughly $422.40, which is below the current price and consistent with the stock having already moved ahead of intrinsic value after the recent rally.